Pfizer stock may not be as hyped as the COVID-19 business looks to wind down. However, with a renewed growth strategy, PFE stock can offer investors growth at a value price.
Shares of COVID vaccine maker Pfizer (PFE) are steadily trending higher again.The $300 billion biopharmaceutical company doesn’t get nearly as much press as it did a few years ago. Undoubtedly, Pfizer was met with much praise following the miraculous marvel that’s since been taken for granted.
Even as the COVID-19 business winds down, Pfizer remains one of this market’s most innovative companies and the 12.3 times trailing earnings multiple does not do its justice.
With a new growth mindset and investment in other intriguing businesses, Pfizer stock seems eager to prove it’s worthy of a much higher multiple. With a stellar management team and discounted growth capabilities, stock attempts to revisit its highs near $60 per share.
Source - database | Page ID - 825
The website www.fpmarkets.com is operated by First Prudential Markets PTY Ltd an entity that is not established in the EU or regulated by an EU National Competent Authority. The entity falls outside the EU regulatory framework i.e. MiFID II and there is no provision for an Investor Compensation Scheme. Read T & Cs
Please confirm, that the decision was made independently at your own exclusive initiative and that no solicitation or recommendation has been made by FP Markets or any other entity within the group.
